



Three Things You Can Never Miss: Multispecialty Review

(02/19/22 @ 8:25 a.m. ET)

Saturday, February 19, 2022

Wills Eye Auditorium

With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment. 2022 Orbital Update.

At the conclusion of the course, participants should be able to:

- 1 Discuss important new advances in the etiologies, diagnosis, and treatment/prevention of eye diseases.
- 2 Identify basic and clinical vision research that can be transformed into improved clinical care.
- 3 Assess the role of new technologies in the evaluation and treatment of eye diseases.
- 4 Describe factors that impact the effective delivery of the highest quality eye care for the public.
- 5 Identify clinical, scientific, and ethical issues confronting the profession.
- 6 Obtain information and tools through multiple facets to help ophthalmologists deliver high and efficient quality of care.

Accreditation Statement:

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Wills Eye Hospital designates this live educational activity for a maximum of 3.75 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement:

It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Brenton D. Finklea, MD	Faculty	Nothing to disclose - 10/01/2021
Kammi B. Gunton, MD	Faculty	Nothing to disclose - 11/29/2021
Natasha Kolomeyer, MD	Faculty	Consulting Fee-Allergan Grant or research support-Allergan Grant or research support-Guardion Health Services Inc Grant or research support-Equinox Grant or research support-Nicox Grant or research support-Olleyes Grant or research support-Santen Pharmaceuticals Grant or research support-Glaukos Corporation Grant or research support-Diopsys Grant or research support-Aerie Pharmaceuticals - 01/14/2022
Sonia Mehta, MD	Faculty	Nothing to disclose - 04/30/2021
Sarah Thornton , MD	Faculty	Nothing to disclose - 04/06/2021
Alison Watson, MD	Faculty	Nothing to disclose - 04/21/2021
Jurij R. Bilyk, MD	Faculty, Planner	Nothing to disclose - 11/28/2021
Bob Penne, MD	Faculty, Planner	Nothing to disclose - 11/10/2021
Ralph C. Eagle Jr., MD	Other Planning Committee Member	Stocks or stock options, excluding diversified mutual funds-Merck - 01/15/2022

